Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies

被引:0
|
作者
Ian S. Blagbrough
Chiara Zara
机构
[1] University of Bath,Department of Pharmacy and Pharmacology
来源
Pharmaceutical Research | 2009年 / 26卷
关键词
efficacy; gene delivery; pharmacodynamics; pharmacokinetics; RNAi;
D O I
暂无
中图分类号
学科分类号
摘要
Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids. This review is focused on the impact of gene and siRNA delivery for studies of efficacy, pharmacodynamics, and pharmacokinetics within the setting of the wide variety of in vivo animal models now used. This critical appraisal of the recent literature sets out the different models that are currently being investigated to bridge from studies in cell lines through towards clinical reality. Whilst many scientists will be familiar with rodent (murine, fecine, cricetine, and musteline) models, few probably think of fish as a clinically relevant animal model, but zebrafish, madake, and rainbow trout are all being used. Larger animal models include rabbit, cat, dog, and cow. Pig is used both for the prevention of foot-and-mouth disease and human diseases, sheep is a model for corneal transplantation, and the horse naturally develops arthritis. Non-human primate models (macaque, common marmoset, owl monkey) are used for preclinical gene vector safety and efficacy trials to bridge the gap prior to clinical studies. We aim for the safe development of clinically effective delivery systems for DNA and RNAi technologies.
引用
收藏
相关论文
共 50 条
  • [31] Gene therapy and DNA delivery systems
    Ibraheem, D.
    Elaissari, A.
    Fessi, H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 459 (1-2) : 70 - 83
  • [32] DNA Gene Therapy in Pediatric Diseases
    Agarwal, Sunita R.
    MOLECULAR THERAPY, 2014, 22 : S127 - S128
  • [33] Gene therapy for mitochondrial DNA diseases
    Taylor, RF
    Chinnery, PF
    Lightowlers, RN
    Turnbull, DM
    NEUROLOGY, 1997, 48 (03) : 4085 - 4085
  • [34] Efficient siRNA delivery using water soluble lipopolymer for anti-anglogenic gene therapy
    Kim, Won Jong
    Chang, Chien-Wen
    Lee, Minhyung
    Kim, Sung Wan
    JOURNAL OF CONTROLLED RELEASE, 2007, 118 (03) : 357 - 363
  • [35] SiRNA gene therapy using albumin as a carrier
    Malhotra, Anshoo
    Mittal, Bhagwant Rai
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (12): : 582 - 587
  • [36] DNA tetrahedron-based nanogels for siRNA delivery and gene silencing
    Xue, Han
    Ding, Fei
    Zhang, Jiao
    Guo, Yuanyuan
    Gao, Xihui
    Feng, Jing
    Zhu, Xinyuan
    Zhang, Chuan
    CHEMICAL COMMUNICATIONS, 2019, 55 (29) : 4222 - 4225
  • [37] Editorial: Remodeling in cardiometabolic diseases: Towards biomarker characterization, target therapy identification, and drug delivery strategies
    Ammar, Hania
    Sharawy, Nivin
    Lehmann, Christian
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [38] Lung specific target gene inhibition following intravenous delivery of siRNA nanocomplexes
    Fewell, Jason
    Sparks, Jeff
    Congo, Richard
    Slobodkin, Gregory
    Rea-Ramsey, Angela
    Pence, Casey
    Matar, Majed
    McClure, Diane
    Rice, Jennifer
    Brunhoeber, Elaine
    Wilkinson, Leslie
    Anwer, Khursheed
    Polach, Kevin
    CANCER RESEARCH, 2011, 71
  • [39] Hormone Therapy and Delivery Strategies against Cardiovascular Diseases
    Acharya, Gayathri
    Hasan, Nurhasni
    Yoo, Jin-Wook
    Lee, Chi H.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2017, 18 (04) : 285 - 302
  • [40] Gene-therapy delivery strategies in cardiology
    Mueller, Oliver J.
    Ksienzyk, Jan
    Katus, Hugo A.
    FUTURE CARDIOLOGY, 2008, 4 (02) : 135 - 150